Fubotv earnings beat by $0.10, revenue topped estimates
Silence Therapeutics PLC (SLN) shares tumbled to a 52-week low, touching down at $3.19 amidst a challenging year for the biotechnology firm. With a market capitalization of $148 million and a current ratio of 11.14, the company maintains strong liquidity despite its recent stock performance. The company, which specializes in the development of gene-silencing therapies for the treatment of serious diseases, has seen its stock price severely retract, reflecting an 85.25% decline over the past year. According to InvestingPro data, the company posted revenue of $43.26 million in the last twelve months, with a gross profit margin of 72.7%. Investors have been cautious as Silence Therapeutics navigates through the complex landscape of drug development and regulatory approvals, with the market sentiment reflecting the high-risk nature inherent in the biotech sector. The 52-week low marks a significant downturn for the company, which is now focusing on strategic moves to regain its footing and reassure stakeholders of its long-term potential. InvestingPro analysis suggests the stock is currently undervalued, with analysts setting price targets ranging from $4 to $75 per share. Discover more insights and 12 additional ProTips with an InvestingPro subscription.
In other recent news, Silence Therapeutics reported a notable increase in revenue for 2024, rising to $43.3 million from $31.6 million in the previous year. This growth was largely attributed to strategic collaborations with companies like AstraZeneca (NASDAQ:AZN) and Hanseo Pharma, which have bolstered the company’s financial performance. Despite this, Morgan Stanley (NYSE:MS) adjusted its price target for Silence Therapeutics to $45, citing changes in the financial model and a lowered probability of success for the drug zerlasiran. Jefferies also revised its price target to $30, maintaining a Buy rating, and highlighted the company’s strategic decision to delay the phase 3 trial of zerlasiran until a partnership is secured.
H.C. Wainwright, however, maintained a positive outlook on Silence Therapeutics, reiterating a $75 price target and emphasizing the company’s strategic focus and solid financial position. The analysts noted that the company’s cash reserves are sufficient to fund operations into 2027, supporting the advancement of its RNAi pipeline. Silence Therapeutics is also progressing with other drug candidates, such as divesiran, which is expected to complete enrollment for its Phase 2 study by the end of 2025. Additionally, the company plans to initiate a Phase 1 trial for SLN548 in the second half of 2025, further expanding its portfolio of RNAi therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.